Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma-Reference-Cited by-同舟云学术

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Published:2016-07-21 Issue:3 Volume:128 Page:384-394
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Krejcik Jakub¹²,Casneuf Tineke³,Nijhof Inger S.¹,Verbist Bie³,Bald Jaime⁴,Plesner Torben²,Syed Khaja⁴,Liu Kevin⁵,van de Donk Niels W. C. J.¹,Weiss Brendan M.⁶,Ahmadi Tahamtan⁴,Lokhorst Henk M.¹,Mutis Tuna¹,Sasser A. Kate⁴

Affiliation:

1. Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands;

2. Institute of Regional Health Science and Department of Hematology, Sections of Internal Medicine, Vejle Hospital and University of Southern Denmark, Vejle, Denmark;

3. Janssen Research & Development, Beerse, Belgium;

4. Janssen Research & Development, LLC, Spring House, PA;

5. Janssen Research & Development, LLC, Raritan, NJ; and

6. Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Abstract

Key Points CD38-expressing immunosuppressive regulatory T and B cells and myeloid-derived suppressor cells were sensitive to daratumumab treatment. Cytotoxic T-cell number, activation, and clonality increased after daratumumab treatment in heavily pretreated relapsed and refractory MM.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/3/384/1358792/384.pdf

Reference36 articles.

1. Ten years of improvement in the management of multiple myeloma: 2000-2010.;Harousseau;Clin Lymphoma Myeloma Leuk,2010

2. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).;Kastritis;Leukemia,2009

3. Improved survival in multiple myeloma and the impact of novel therapies.;Kumar;Blood,2008

4. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.;Kumar;Leukemia,2012

5. The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.;Dosani;Blood Cancer J,2015

Cited by 677 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity;Blood Cancer Journal;2024-02-06

2. Mechanism of Qizhen decoction-mediated maturation of DC cells to activate the IL-12/JAK2/STAT4 pathway to sensitise PD-1 inhibitors in the treatment of colorectal cancer;Journal of Ethnopharmacology;2024-02

3. Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism;Cell Reports Medicine;2024-02

4. Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA;American Journal of Hematology;2024-01-31

5. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma;New England Journal of Medicine;2024-01-25